文献速递肝胆胰外科围术期管理与 ERAS

生物学交界可切除胰腺癌是遗传与免疫侵袭性亚型:回顾性研究

Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study.
PubMed 文献 · Ann Surg · 2026-05-13

该回顾性研究分析144例未接受新辅助治疗直接手术的胰腺导管腺癌患者,按术前CA19-9分为三组。CA19-9≥500 U/mL的生物学交界可切除患者癌症特异性生存更差,驱动基因突变累积、CDKN2A/p16改变和腹膜复发呈阶梯式增加,肿瘤浸润淋巴细胞中TLS阳性率逐步下降。高CA19-9识别出基因组改变增多和免疫抑制微环境的侵袭性亚群。

要点

  • 术前CA19-9≥500 U/mL的胰腺癌患者CSS显著更差(P=0.03)。
  • CA19-9升高与≥3个驱动基因突变频率阶梯式增加相关(Ptrend=0.01)。
  • TLS阳性率随CA19-9升高逐步下降(Ptrend=0.001),腹膜复发逐步增加(Ptrend=0.047)。

核心结论

  • 高术前CA19-9(≥500 U/mL)识别出基因组改变增加和免疫抑制微环境的生物学侵袭性胰腺癌亚群,即使影像学可切除也属高危。

研究设计与样本

  • 回顾性分析144例接受 upfront 手术切除且未行新辅助治疗的胰腺导管腺癌患者,按术前CA19-9分为<37 U/mL(n=30)、37-499 U/mL(n=76)和≥500 U/mL(n=38)三组。

主要发现

  • CA19-9≥500 U/mL组CSS显著差于<37 U/mL组(P=0.03)。
  • 携带≥3个驱动基因改变(KRAS、TP53、CDKN2A、SMAD4)的肿瘤频率随CA19-9分层阶梯式增加(Ptrend=0.01)。
  • CDKN2A/p16改变随CA19-9升高呈阶梯式增加(Ptrend=0.006)。
  • TLS阳性率随CA19-9升高逐步下降(Ptrend=0.001),CD8⁺T细胞密度逐步降低但差异未达统计学显著性(Ptrend=0.067)。
  • 腹膜复发在各组间呈阶梯式增加(Ptrend=0.047)。

临床怎么用

  • 术前CA19-9≥500 U/mL可作为高危胰腺癌标志,提示需强化围手术期策略,即使影像学判断为可切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biological borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) refers to anatomically resectable tumors with markedly elevated serum CA19-9 levels (≥500 U/mL). This subtype is associated with poor prognosis, yet its molecular and immunopathological features remain incompletely understood. METHODS: We retrospectively analyzed 144 patients who underwent upfront surgical resection for PDAC without neoadjuvant therapy. Patients were stratified into three groups according to preoperative CA19-9: <37 U/mL (n=30), 37-499 U/mL (n=76), and ≥500 U/mL (biological BR; n=38). Clinicopathological characteristics, cancer-specific survival (CSS), driver gene alterations (KRAS, TP53, CDKN2A, SMAD4), and immune microenvironment parameters, including tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLS), were evaluated. RESULTS: CSS was significantly worse in patients with CA19-9 ≥500 U/mL compared with those <37 U/mL (P = 0.03). A significant stepwise increase in mutational burden was observed, with the frequency of tumors harboring ≥3 driver gene alterations rising across CA19-9 strata (Ptrend = 0.01). CDKN2A/p16 alterations also demonstrated a stepwise increase with higher CA19-9 levels (Ptrend = 0.006). TLS positivity declined progressively with increasing CA19-9 (Ptrend = 0.001), paralleled by a stepwise reduction in CD8⁺ T-cell density, although the difference did not reach statistical significance (Ptrend = 0.067). Moreover, peritoneal recurrence exhibited a stepwise increase across the groups (Ptrend = 0.047). CONCLUSIONS: High preoperative CA19-9 identifies a biologically aggressive PDAC subset with increased genomic alterations and an immunosuppressive microenvironment. Recognizing CA19-9 ≥500 U/mL as a marker of high-risk disease may guide intensified perioperative strategies, even in cases deemed resectable by imaging.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Arai Y, Masuda A, Tsujimae M, et al. Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study. Ann Surg. 2026. PMID: 42121272. doi:10.1097/SLA.0000000000007075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。